Journals / Türk Kardiyoloji Derneği Arşivi / 2012 / Cilt: 40 - Sayı: 6

Evaluation of serum adiponectin levels in patients with obstructive sleep apnea syndrome

Tıkayıcı uyku apnesi sendromlu hastaların serum adiponektin düzeylerinin değerlendirilmesi

Pages
505–512
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum adiponectin levels are related to the severity of OSAS and arterial oxygen saturation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Serum adiponectin levels have been found to be lower in patients with obesity, hypertension, and coronary artery diseases.
📊
Key Findings & Data:Study design: In 62 OSAS patients (39 males, 23 females) and 32 controls (23 males, 9 females) determined by polisomnography, serum adiponectin levels were analyzed by the ELISA method.
💡
Conclusion & Impact:Serum adiponectin levels are related to the severity of OSAS and arterial oxygen saturation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Serum adiponectin levels have been found to be lower in patients with obesity, hypertension, and coronary artery diseases. In this study, we aimed to evaluate serum adiponectin levels in patients with obstructive sleep apnea syndrome (OSAS) and to correlate these levels with the severity of OSAS. Study design: In 62 OSAS patients (39 males, 23 females) and 32 controls (23 males, 9 females) determined by polisomnography, serum adiponectin levels were analyzed by the ELISA method. Patients were classified as having either mild (apnea hypopnea index, AHI: 5-14), moderate (AHI: 15-29) or severe (AHI ≥30) OSAS, and controls were defined as AHI 0.05) in our study population. There was no significant difference in the number of hypertensive, diabetics, or smokers between the patients and controls. While serum TC, TG, and HDL cholesterol levels were not significantly different between two groups, the serum adiponectin levels of patients (3.0±3.4 μg/dl) were significantly lower than those of the controls (5.2±5.2 μg/dl, p=0.01). While serum adiponectin levels showed a significantly negative correlation with AHI (r= 0.221, p=0.03), there was a significantly positive correlation with minimum and mean oxygen saturations (r=0.213, p=0.04 and r=0.205, p=0.05). Conclusion: S erum adiponectin levels were significantly lower in patients with OSAS, especially for those in the severe OSAS group. Serum adiponectin levels are related to the severity of OSAS and arterial oxygen saturation.

Özet

Amaç: Serum adiponektin düzeylerinin obezite, hipertansiyon ve koroner arter hastalığı olan hastalarda daha düşük olduğu saptanmıştır. Çalışmamızda tıkayıcı uyku apnesi sendromunda (TUAS) serum adiponektin düzeyleri ve hastalığın şiddeti ile bu düzeylerin ilişkisi değerlendirildi. Çalışma planı: P olisomnografik yöntemle tanı konan TUASlı 62 hasta (39 erkek, 23 kadın) ve 32 olguluk kontrol (23 erkek, 9 kadın) grubunda serum adiponektin düzeyleri ELISA yöntemi ile ölçüldü. Hastalar apne hipopne indeksine (AHİ) göre hafif (AHİ: 5-14), orta (AHİ: 15-29) ve ağır (AHİ ≥30) TUAS olarak sınıflandırıldı. Kontrol grubu AHİ 0.05). Hasta ve kontrol grupları arasında hipertansiyonu ve diyabeti olanlar ile sigara içenlerin sayısı açısından da anlamlı bir fark saptanmadı. Serum TK, TG ve HDL kolesterol düzeyleri, hasta ve kontrol grubu arasında anlamlı bir fark oluşturmazken; serum adiponektin düzeyleri, hasta grubunda (3.0±3.4 μg/dl), kontrol grubuna (5.2±5.2 μg/dl) göre anlamlı olarak daha düşüktü (p=0.01). Serum adiponektin düzeyleri, AHİ ile anlamlı negatif korelasyon, (r=0.221, p=0.03); minimum ve ortalama oksijen satürasyonları ile anlamlı olarak pozitif korelasyon gösterdi (r=0.213, p=0.04 ve r=0.205, p=0.05). Sonuç: TUASlı hastalarda, özellikle ağır TUAS grubunda, serum adiponektin düzeyleri anlamlı olarak azalmaktadır. Serum adiponektin düzeyleri, TUAS şiddeti ve arteriyel oksijen satürasyonları ile ilişkili bulunmuştur.

🔖

Cite This Article

DURSUNOĞLU, N., DURSUNOĞLU, D., ROTA, S., ÖZTÜRK, E., ÖZKURT, S. (2022). Evaluation of serum adiponectin levels in patients with obstructive sleep apnea syndrome. Türk Kardiyoloji Derneği Arşivi, Cilt: 40 - Sayı: 6, 505–512. https://ajindex.com/articles/633066

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dursunoğlu D, Dursunoğlu N. Cardiovascular diseases in obstructive sleep apnea. Tuberk Toraks 2006;54:382-96
  2. Dursunoğlu N, Dursunoğlu D. Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis. Tuberk Toraks 2005;53:299-306
  3. Dursunoğlu D. Uyku apne ve kardiyovasküler hastalıklar. İstanbul: Özlem Matbaacılık; 2009
  4. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003;41:1429-37
  5. Dursunoglu N, Dursunoglu D, Ozkurt S, Tanriverdi H, Evrengül H, Kiter G. Severe sleep apnea syndrome diagnosed with acute myocardial infarction. Asian Cardiovasc Thorac Ann 2007;15:e3-6
  6. Dursunoglu D, Dursunoglu N, Evrengül H, Ozkurt S, Kuru O, Kiliç M, et al. Impact of obstructive sleep apnoea on left ventricular mass and global function. Eur Respir J 2005;26:283-8
  7. Dursunoğlu N, Dursunoğlu D, Kiliç M. Impact of obstructive sleep apnea on right ventricular global function: sleep apnea and myocardial performance index. Respiration 2005;72:278- 84
  8. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002;166:159-65
  9. Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005;127:2076-84
  10. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6
  11. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49
  12. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007;49:531-8
  13. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006;26:871-6
  14. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004;110:3842-8
  15. Hotta K, Funahashi T, Ar